Business Context and Reporting Period
This Form 8-K Current Report was filed by Cardiff Oncology, Inc. on May 27, 2026. The filing addresses a material definitive agreement dispute involving the Company's License Agreement dated March 13, 2017, with Nerviano Medical Sciences S.r.l. ("NMS").
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal proceedings and contract status rather than financial performance data.
Material Changes and Events
- Litigation Initiation: On May 19, 2026, Cardiff filed a lawsuit against NMS in the U.S. District Court for the Southern District of California. The suit disputes NMS's claim that Cardiff breached the License Agreement by not naming Dr. Barbara Valsasina as a joint inventor on U.S. Patents 12,144,813 and 12,263,173.
- Agreement Termination Notice: On May 27, 2026, NMS notified Cardiff in writing of its intent to terminate the Agreement under Section 11.3.
- Alleged Breaches by NMS: NMS cites two primary reasons for termination: (1) failure to correct inventorship on the Cardiff Patents to include Dr. Valsasina; and (2) failure to use Commercially Reasonable Efforts to develop onvansertib and obtain Regulatory Approvals.
- Company Response: Cardiff has declared NMS's termination notice legally ineffective, factually unsupported, and procedurally improper, stating it will continue to perform under the Agreement.
Outlook, Risks, and Contingencies
Legal Contingency: The Company is currently engaged in active litigation to secure a declaratory judgment that it did not breach the Agreement and to obtain injunctive relief requiring NMS to continue performance. The outcome of this dispute is a material contingency affecting the Company's rights to the licensed technology and the onvansertib program.
Risk Factors: If the termination is upheld or the litigation is resolved unfavorably, Cardiff may lose rights to the licensed assets, potentially halting development of onvansertib and impacting future revenue streams.
Investor Verification Checklist
- Verify the current status of the lawsuit filed in the Southern District of California.
- Confirm the specific terms of the License Agreement regarding inventorship correction and Commercially Reasonable Efforts.
- Assess the impact of a potential loss of the NMS license on the onvansertib development pipeline.
- Review subsequent filings for updates on the litigation or any settlement discussions.